ArticleEClinicalMedicine2026
CGM-derived postprandial glucose with IcoSema versus other insulin regimens: a
Article in EClinicalMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Impaired insulin and incretin responses, alongside elevated postprandial glucose (PPG) levels after meals, are hallmarks of type 2 diabetes (T2D) and can lead to postprandial hyperglycaemia. This Methods: In this Findings: Data from 1650 participants were analysed. In both trials, an average of 2.3 meals/day/participant were detected. IcoSema treatment resulted in statistically significantly lower mean peak PPG increment, 90-min PPG increment, and 120-min PPG increment values and a faster time to return to normal glucose levels versus once-weekly basal insulin (all Interpretation: IcoSema provided statistically significantly better PPG control than once-weekly icodec and similar PPG control versus daily BBT with only one weekly injection. Future studies that prospectively evaluate CGM-derived PPG outcomes and their clinical relevance across different meal compositions in real-world treatment settings would be beneficial. Funding: Novo Nordisk A/S.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.